Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Historical Acquisition Tree
Alternative names
Key: Marker Therapeutics (1) Acquired (6)
cyclophosphamide (cytoxan) (1 trial)
durvalumab (imfinzi) (1 trial)
fralpha peptide (1 trial)
fralpha vaccine (1 trial)
sargramostim (leukine) (1 trial)
tpiv200 (1 trial)
Zedenoleucel (1 trial)
Key: Marker Therapeutics (1) Acquired (1)
her-2/neu peptide vaccine (1 trial)
mt-601 (1 trial)
Leukemia (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Trials (6 total)
Trial APIs (9 total)